Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
174.2 BRL | +0.72% | +1.13% | -9.49% |
04-26 | TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90 | MT |
04-26 | Jefferies Adjusts Gilead Sciences' Price Target to $80 From $95 | MT |
Sales 2024 * | 27.54B 141B 2,205B | Sales 2025 * | 27.99B 143B 2,241B | Capitalization | 81.58B 417B 6,530B |
---|---|---|---|---|---|
Net income 2024 * | 428M 2.19B 34.26B | Net income 2025 * | 6.5B 33.22B 520B | EV / Sales 2024 * | 3.58 x |
Net Debt 2024 * | 16.88B 86.35B 1,352B | Net Debt 2025 * | 9.29B 47.49B 743B | EV / Sales 2025 * | 3.25 x |
P/E ratio 2024 * |
137
x | P/E ratio 2025 * |
12.4
x | Employees | 18,000 |
Yield 2024 * |
4.75% | Yield 2025 * |
4.96% | Free-Float | 99.9% |
Latest transcript on Gilead Sciences, Inc.
1 day | +0.72% | ||
1 week | +1.13% | ||
Current month | -3.83% | ||
1 month | -3.96% | ||
3 months | -10.76% | ||
6 months | -11.64% | ||
Current year | -9.49% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 58 | 28/02/19 |
Andrew Dickinson
DFI | Director of Finance/CFO | 54 | 31/12/15 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 11/04/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Anthony Welters
BRD | Director/Board Member | 69 | 16/10/20 |
Director/Board Member | 71 | 31/12/17 | |
Ted Love
BRD | Director/Board Member | 65 | 01-31 |
Date | Price | Change | Volume |
---|---|---|---|
25/04/24 | 174.2 | +0.72% | 2,410 |
24/04/24 | 173 | +0.36% | 325 |
23/04/24 | 172.4 | -0.50% | 1,100 |
22/04/24 | 173.2 | +0.55% | 201 |
19/04/24 | 172.3 | -0.69% | 886 |
Delayed Quote Sao Paulo, April 25, 2024 at 02:40 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- GILD Stock
- GILD34 Stock